A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
NCT ID: NCT06890611
Last Updated: 2025-10-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
125 participants
INTERVENTIONAL
2025-03-25
2025-09-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
NCT06901349
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
NCT06643728
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT06603571
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
NCT05822830
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
NCT06373146
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bimagrumab Dose 1 Reference Material
Participants will receive a single dose of bimagrumab subcutaneously (SC)
Bimagrumab
Administered SC
Bimagrumab Dose 1 Test Material + Tirzepatide (Coadministration)
Participants will receive a single dose of bimagrumab SC and a single dose of tirzepatide SC
Bimagrumab
Administered SC
Tirzepatide
Administered SC
Bimagrumab Dose 1 Test Material + Tirzepatide (Coformulation)
Participants will receive a single dose of bimagrumab with tirzepatide SC
Bimagrumab + Tirzepatide Coformulation
Administered SC
Bimagrumab Dose 2 Test Material + Tirzepatide (Coadministration)
Participants will receive bimagrumab SC and tirzepatide SC for 4 weeks
Bimagrumab
Administered SC
Tirzepatide
Administered SC
Bimagrumab Dose 2 Test Material + Tirzepatide (Coformulation)
Participants will receive bimagrumab with tirzepatide SC for 4 weeks
Bimagrumab + Tirzepatide Coformulation
Administered SC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bimagrumab
Administered SC
Tirzepatide
Administered SC
Bimagrumab + Tirzepatide Coformulation
Administered SC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a body mass index (BMI) within the range of 22.0 to 30.0 kilograms per square meter (kg/m2), inclusive
Exclusion Criteria
* Have a self-reported increase or decrease in body weight, greater than 5 kilograms (kg), within 3 months prior to screening
* Have uncontrolled high blood pressure
* Have taken medications or alternative remedies to promote weight loss within 3 months prior to screening
18 Years
64 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fortrea Clinical Research Unit
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
J4Z-MC-GIDG
Identifier Type: OTHER
Identifier Source: secondary_id
27286
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.